Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141542 · ClinicalTrials.gov registry record · Phase 1
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase 1 study of Metastatic Melanoma, sponsored by F. Stephen Hodi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT02141542 is a Phase 1 study of Metastatic Melanoma that has completed, run by F. Stephen Hodi, MD. The registered enrollment target is 15 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02141542, a Phase 1 study of Metastatic Melanoma, has completed, sponsored by F. Stephen Hodi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
Conditions Studied
Interventions
- DRUG Tremelimumab
- DRUG MEDI3617
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141542
The ClinicalTrials.gov registry entry for NCT02141542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (82% lower). The listed sponsor is F. Stephen Hodi, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Tremelimumab is the first listed.
NCT02141542 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02141542 about?
NCT02141542 is a clinical study titled "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma". This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
What is the current status of trial NCT02141542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2020-09-23.
What conditions does trial NCT02141542 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT02141542?
The interventions under investigation include: Tremelimumab (DRUG), MEDI3617 (DRUG).
Who is sponsoring clinical trial NCT02141542?
This trial is sponsored by F. Stephen Hodi, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141542 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.